ライフサイエンスコーパス: maintenance therapy

1 idence of AAV relapse compared with standard maintenance therapy.

2 the efficacy of tofacitinib as induction and maintenance therapy.

3 nosis, after three cycles of RVD, and before maintenance therapy.

4 al nervous system prophylaxis while omitting maintenance therapy.

5 (1344 patient-months for the cohort) during maintenance therapy.

6 e taking inhaled glucocorticoid-based triple maintenance therapy.

7 erapy to the primary tumour site followed by maintenance therapy.

8 progress as part of induction, salvage, and maintenance therapy.

9 he treatment of periodontitis or periodontal maintenance therapy.

10 ared with gemcitabine plus erlotinib used as maintenance therapy.

11 third, suggesting a role as postchemotherapy maintenance therapy.

12 exed alone followed by indefinite pemetrexed maintenance therapy.

13 etastatic disease, especially when used as a maintenance therapy.

14 tekinumab was also evaluated as subcutaneous maintenance therapy.

15 t when added to inhaled corticosteroid (ICS) maintenance therapy.

16 , and employ the use of aggressive long-term maintenance therapy.

17 cts of using topical glucocorticosteroids as maintenance therapy.

18 a) in patients receiving regular periodontal maintenance therapy.

19 ued with up to 12 further 3-weekly cycles of maintenance therapy.

20 d on lasers treating inflamed pockets during maintenance therapy.

21 years and continued to receive ipilimumab as maintenance therapy.

22 th normokalemia maintained during 12 days of maintenance therapy.

23 munotherapy and in some cases during ongoing maintenance therapy.

24 ce of inflammation, despite continued use of maintenance therapy.

25 rapamycin+mycophenolate mofetil treatment as maintenance therapy.

26 ts to lenalidomide maintenance therapy or no maintenance therapy.

27 Responding patients could receive maintenance therapy.

28 ant treatment must include the need for such maintenance therapy.

29 partial response (PR) with R-FCM were given maintenance therapy.

30 cycles, followed by pomalidomide-prednisone maintenance therapy.

31 dependent HIV-infected patients on methadone maintenance therapy.

32 ol, independent of baseline severity and the maintenance therapy.

33 < .05) in patients who received ustekinumab maintenance therapy.

34 RIT consolidation and/or extended rituximab maintenance therapy.

35 ction, and sirolimus with or without CTLA4Ig maintenance therapy.

36 (153 patients) or MP (154 patients) without maintenance therapy.

37 mportant in assessing the clinical impact of maintenance therapy.

38 rs associated with compliance to periodontal maintenance therapy.

39 nued ipilimumab or placebo every 12 weeks as maintenance therapy.

40 f response and remission with ustekinumab as maintenance therapy.

41 none of the drugs evaluated is approved for maintenance therapy.

42 Eight patients started maintenance therapy.

43 duction followed by belatacept and sirolimus maintenance therapy.

44 y microvascular injury compared to prasugrel maintenance therapy.

45 ement in residual periodontal pockets during maintenance therapy.

46 ne for four or six 21-day cycles followed by maintenance therapy.

47 a randomized study to determine the optimal maintenance therapy.

48 nut OIT (300 mg or 3000 mg, respectively) as maintenance therapy.

49 compared with PR/RP alone during periodontal maintenance therapy.

50 phine (BUP) are widely prescribed for opiate maintenance therapy.

51 important to establish the potential role of maintenance therapy.

52 terruptions, booster therapies and induction-maintenance therapies.

53 ered after the six cycles of chemotherapy as maintenance therapy (15 mg/kg once every 3 weeks) until

54 At no risk of viral escape, maintenance therapy, 4 days per week, would quasiunivers

55 During maintenance therapy, 4 patients experienced reactivation

56 sulting in a significant shorter duration of maintenance therapy (5 vs 17 months in MPR-R), irrespect

57 of cabotegravir plus rilpivirine long-acting maintenance therapy administered intramuscularly every 8

58 Effective maintenance therapies after chemoradiotherapy for lung c

59 nd second primary malignancies, lenalidomide maintenance therapy after ASCT significantly improved ti

60 Thalidomide maintenance therapy after autologous stem cell transplan

61 Purpose Lenalidomide maintenance therapy after autologous stem-cell transplan

62 ble non-small-cell lung cancer when given as maintenance therapy after chemoradiation.

63 The efficacy and safety of lenalidomide as maintenance therapy after chemotherapy-based second-line

64 We investigated whether ticagrelor maintenance therapy after revascularized ST-segment-elev

65 Rituximab maintenance therapy after transplantation prolonged even

66 al investigated the efficacy of lenalidomide maintenance therapy after transplantation.

67 ipients prescribed cyclosporine/azathioprine maintenance therapy (aIRR 1.79, 95% CI 1.09-2.93, compar

68 oved progression-free survival compared with maintenance therapy alone.

69 EX and IVIG both have high response rates as maintenance therapies and are reasonable therapeutic opt

70 s between the end of induction and week 7 of maintenance therapy and were treated with chemotherapy a

71 tense and dose-dense regimens, to the use of maintenance therapies, and most recently the addition of

72 n were assigned to delayed consolidation and maintenance therapy, and allo-HSCT was scheduled in pati

73 s for induction therapy, corticosteroids for maintenance therapy, and cannabis in any role.

74 standing of EoE progression and the need for maintenance therapy, and continue development of diagnos

75 ous as well as intravenous immunoglobulin as maintenance therapy, and newer immunomodulating drugs ca

76 ired the presence of all three agents during maintenance therapy, and resulted in graft acceptance fo

77 s, optimal treatment end points, the role of maintenance therapy, and treatment of refractory EoE.

78 y were advised to continue this treatment as maintenance therapy, and women who required both antipsy

79 -, or caregiver-administered oral 6MP during maintenance therapy; and (4) completion of at least 6 mo

80 itional studies are needed to find effective maintenance therapy approaches.

81 , and two trials with rituximab as remission maintenance therapy are ongoing.

82 ion of the optimal duration and frequency of maintenance therapy as well as development of targeted t

83 s a novel tocolytic agent for both acute and maintenance therapy, as it inhibits both myometrial cont

84 evaluated and resampled and received regular maintenance therapy at 3, 6, and 12 months after treatme

85 We investigated whether rituximab maintenance therapy at a dose of 375 mg per square meter

86 dependent HIV-infected patients on methadone maintenance therapy at a drug abuse outpatient center.

87 ecrosis factor antagonists for induction and maintenance therapy at diagnosis or at early stages of s

88 ; and (4) completion of at least 6 months of maintenance therapy at the time of study enrollment.

89 ceived induction, consolidation, and interim maintenance therapy before they began delayed intensific

90 reatment may help patients with intermittent maintenance therapy between MTD cycles and prevent tumor

91 As a two-drug maintenance therapy, cabotegravir plus rilpivirine provi

92 a bortezomib-based induction and bortezomib maintenance therapy compared with conventional induction

93 high-dose cytarabine and anthracycline, and maintenance therapy comprising ATRA, oral methotrexate,

94 (AML) have a poor prognosis, and innovative maintenance therapy could improve their outcomes.

95 The advent of maintenance therapy could potentially improve outcomes o

96 Maintenance therapy did not contain ASNase.

97 addition of formoterol to mometasone furoate maintenance therapy did not increase the risk of serious

98 Long-term rituximab maintenance therapy does not improve EFS, which was the

99 s, with or without concomitant D-amphetamine maintenance therapy during these 14 sessions (5 mg/kg/da

100 Continuation maintenance therapy entails the ongoing administration o

101 platin +/- enzastaurin [PCE/PC]) followed by maintenance therapy (enzastaurin/placebo).

102 receiving rATG induction and steroid-sparing maintenance therapy evaluates the effect of small change

103 a total of four administrations, followed by maintenance therapy every 12 weeks in patients who remai

104 n therapy received obinutuzumab or rituximab maintenance therapy every 2 months for up to 2 years.

105 receive ipilimumab at 10 mg/kg or placebo as maintenance therapy every 3 months until disease progres

106 eeks for four cycles, followed by pemetrexed maintenance therapy every 3 weeks.

107 ccurred in patients who received ustekinumab maintenance therapy every 8 weeks.

108 ndomly assigned; 10 patients did not receive maintenance therapy (five on each arm).

109 Maintenance therapy followed 8 weeks later with intraven

110 rmine the safety and efficacy of ixazomib as maintenance therapy following ASCT.

111 Maintenance therapy following autologous stem cell trans

112 bevacizumab or pemetrexed is efficacious as maintenance therapy for advanced nonsquamous NSCLC.

113 posure to oral 6-mercaptopurine (6MP) during maintenance therapy for childhood acute lymphoblastic le

114 recommendations regarding 6-MP intake during maintenance therapy for childhood ALL should aim to simp

115 Administration as maintenance therapy for patients with ovarian cancer in

116 Local consolidative therapy with or without maintenance therapy for patients with three or fewer met

117 Its efficacy as maintenance therapy for patients with ulcerative colitis

118 ith esomeprazole on-demand versus continuous maintenance therapy for symptom control in patients with

119 bitors and immunomodulatory drug combination maintenance therapy for this patient population.

120 more effective than placebo as induction and maintenance therapy for ulcerative colitis.

121 mg/kg for four cycles, followed by nivolumab maintenance therapy for up to 2 years.

122 Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly ora

123 Grade 3 adverse events in the maintenance therapy group were fatigue (n=1) and anaemia

124 rejection was not uniform in the belatacept maintenance therapy groups, the frequency of rejection l

125 after induction therapy to one of the three maintenance therapy groups.

126 Maintenance therapy has become a hot field in myeloma, a

127 Rituximab maintenance therapy has been shown to improve progressio

128 In addition, maintenance therapy has emerged as a valid approach, and

129 eatment of certain hematologic malignancies, maintenance therapy has only recently become a treatment

130 h multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survi

131 Several aspects of maintenance therapy have raised considerable debate in t

132 02) and the use of calcineurin-based therapy maintenance therapy (hazard ratio 0.53; confidence inter

133 to examine outcomes associated with hormonal maintenance therapy (HMT) compared with routine observat

134 1.62 IC 1.09-2.41 p<0.02) and the use of CNI maintenance therapy (HR 0.53 IC 0.34-0.82 p<0.004).

135 Lenalidomide maintenance therapy improved median progression-free sur

136 olerated as add-on therapy to ICS with other maintenance therapies in children with severe symptomati

137 corticosteroids (ICSs) with or without other maintenance therapies in patients with moderate or sever

138 concentrated platelets after a loading dose/maintenance therapy in a time-dependent manner under in

139 er doses within ICS/long-acting beta-agonist maintenance therapy in accordance with the stepwise appr

140 nd well tolerated when added to at least ICS maintenance therapy in adolescent patients with moderate

141 sion resulted in long-term remission without maintenance therapy in approximately 15% of patients.

142 phase 2 clinical trial evaluating rituximab maintenance therapy in chronic lymphocytic leukemia (CLL

143 ravenous (IV) administration of rituximab as maintenance therapy in follicular lymphoma.

144 y being tested in phase 3 clinical trials as maintenance therapy in ovarian cancer and as a treatment

145 exploring the benefit of adding androgens to maintenance therapy in patients 60 years of age or older

146 doxorubicin, followed by single-agent TH-302 maintenance therapy in patients with first-line advanced

147 Data on the benefit of PARP inhibition as maintenance therapy in patients with germline BRCA1 or B

148 e of oral 5-aminosalicylate for induction or maintenance therapy in patients with moderate disease, a

149 umab as 8-week induction therapy and 44-week maintenance therapy in patients with moderate-to-severe

150 red lenalidomide maintenance therapy with no maintenance therapy in patients with newly diagnosed mul

151 nts an additional option for post-transplant maintenance therapy in patients with newly diagnosed mul

152 s the efficacy and safety of lenalidomide as maintenance therapy in patients with previously treated

153 ukin-12 and interleukin-23, as induction and maintenance therapy in patients with ulcerative colitis

154 vestigated in phase III clinical trials as a maintenance therapy in platinum-sensitive ovarian cancer

155 sthma control and non-inferior to budesonide maintenance therapy in preventing exacerbations.

156 idence to support the benefit of periodontal maintenance therapy in preventing tooth loss.

157 ts who received thalidomide in induction and maintenance therapy in the Total Therapy (TT) 2 trial (i

158 The effectiveness of rituximab maintenance therapy in the treatment of chronic lymphocy

159 We aimed to assess lenalidomide maintenance therapy in these high-risk patients.

160 thiopurine or methotrexate), or vedolizumab maintenance therapy in those who successfully achieve sy

161 is factor-alpha (TNFalpha), was evaluated as maintenance therapy in TNFalpha antagonist-naive adults

162 d caution against the use of sirolimus-based maintenance therapy, in HIV-positive individuals undergo

163 Potential rationales for maintenance therapy include increased exposure to effect

164 Maintenance therapy includes pemetrexed continuation for

165 Lenalidomide maintenance therapy, initiated at day 100 after hematopo

166 transplantation but higher with azathioprine maintenance therapy (IRR=1.35, 95% CI 1.03-1.77).

167 ulto MM-015 trials suggest that lenalidomide maintenance therapy is associated with a higher incidenc

168 Maintenance therapy is associated with improved survival

169 dependent HIV-infected patients on methadone maintenance therapy is high.

170 dding to the effects of standard treatments, maintenance therapy is likely to help incrementally exte

171 f plasmapheresis (PLEX) vs immunoglobulin as maintenance therapy is unclear for this childhood diseas

172 Pemetrexed continuation maintenance therapy is well-tolerated and offers superio

173 The greatest experience of maintenance therapy is with antiangiogenic agents.

174 divided by the planned protocol dose during maintenance therapy; its association with genotype was e

175 nalysis suggests no effect of stable lithium maintenance therapy (lithium levels in therapeutic range

176 which the endogenous immune system supports maintenance therapy, long-term disease control, or even

177 nt with improved results; posttransplant TKI maintenance therapy may also provide survival benefit.

178 Induction of remission followed by maintenance therapy might prove to be an integral part o

179 In both groups, the periodontal maintenance therapy minimized the negative effect of the

180 with opioid dependence undergoing methadone maintenance therapy (MMT) in a randomized, double-blind,

181 ioid-dependent patients undergoing methadone-maintenance-therapy (MMT) and healthy controls (HCs) wer

182 or more of prior GC exposure, not receiving maintenance therapy (n = 15); (2) currently receiving bu

183 ithdrawal and received placebo (n = 182), or maintenance therapy (n = 193).

184 ed and randomly assigned to receive ixazomib maintenance therapy (n=395) or placebo (n=261).

185 uestion the long-term safety of azithromycin maintenance therapy.Objectives: To assess the effects of

186 l transplantation (alloHCT) and single-agent maintenance therapy of 12 months is feasible and favorab

187 therapy and had no recurring symptoms under maintenance therapy of 5 mg prednisolone during the 3-ye

188 Pemetrexed or bevacizumab is used for maintenance therapy of advanced nonsquamous non-small-ce

189 fections after ambulatory surgeries and as a maintenance therapy of atopic dermatitis (AD).

190 in early-stage infections and protocols for maintenance therapy of chronic infections.

191 ng dose of ticagrelor and were randomized to maintenance therapy of ticagrelor (n=56) or prasugrel (n

192 on of this lead-contaminated opium by Opioid Maintenance Therapy (OMT)-prescribed opium tincture is r

193 We aimed to assess the effect of lithium maintenance therapy on estimated glomerular filtration r

194 A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting

195 an 40 years, the long-term effect of lithium maintenance therapy on renal function has been debated.

196 induction, and 251 patients to lenalidomide maintenance therapy or no maintenance therapy.

197 Patients were randomly assigned (1:1) to maintenance therapy or observation (MT/O) or to LCT to a

198 umab for 24 months and indefinite pemetrexed maintenance therapy or to 4 cycles of carboplatin and pe

199 y assigned 240 patients to receive rituximab maintenance therapy or to undergo observation after auto

200 antibiotics or vedolizumab for induction or maintenance therapy, or methotrexate for induction thera

201 In the trial of maintenance therapy, patients in either cohort who had a

202 investigate association between peri-implant maintenance therapy (PIMT) and the frequency of peri-imp

203 rein at assessing the impact of peri-implant maintenance therapy (PIMT) on the prevention of peri-imp

204 Eighty-five patients received maintenance therapy (placebo, n = 41; sunitinib, n = 44)

205 ; the risk was similar to that of budesonide maintenance therapy plus as-needed SABA.

206 is study followed individuals in periodontal maintenance therapy (PMT) over 6 years and longitudinall

207 nce of periodontitis (RP) during periodontal maintenance therapy (PMT) programs have not been previou

208 iodontitis and tooth loss during periodontal maintenance therapy (PMT) programs have not previously b

209 treat persistent pockets during periodontal maintenance therapy (PMT) require further investigation.

210 lamed periodontal pockets during periodontal maintenance therapy (PMT), but evidence for efficacy fro

211 iodontitis and tooth loss during periodontal maintenance therapy (PMT).

212 lantation, though similar indications in the maintenance therapy population have been described.

213 In the pooled (randomized and nonrandomized) maintenance therapy population, histologic improvement c

214 At week 44 in the randomized maintenance therapy population, the mean GHAS remained r

215 herapy and 3.7 mug/mL at steady-state during maintenance therapy produced optimal outcomes in patient

216 redictable risk variables of two periodontal maintenance therapy programs over a 12-month period.

217 Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progres

218 III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progress

219 Sorafenib maintenance therapy reduces the risk of relapse and deat

220 TERPRETATION: Lenalidomide is an efficacious maintenance therapy reducing the relative risk of progre

221 y weight, or no norethandrolone for a 2-year maintenance therapy regimen.

222 Results under loading dose and maintenance therapy regimens were nearly identical.

223 e time between end of induction and start of maintenance therapy resulted in inferior EFS (hazard rat

224 e 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progr

225 Maintenance therapy (second line or more) with single-ag

226 Posttransplantation maintenance therapy should be investigated in prospectiv

227 respectively; yet, current data suggest that maintenance therapy should continue at least until progr

228 , and lenalidomide, followed by lenalidomide maintenance therapy, showed promising results without se

229 D-amphetamine maintenance therapy shows promise as a treatment for peo

230 Pemetrexed maintenance therapy significantly improved overall survi

231 d of anti-CD25 antibody induction and triple maintenance therapy (steroids, mycophenolate mofetil, an

232 To date, switch maintenance therapy strategies with pemetrexed and erlot

233 gression-free survival noted with pemetrexed maintenance therapy, such treatment is an option for pat

234 ed with lower disease activity at the end of maintenance therapy than either histologic or endoscopic

235 acitinib was more effective as induction and maintenance therapy than placebo.

236 lues from the screening and day-0 visits) to maintenance therapy (the average of values from the week

237 s at relapse reduce the potential benefit of maintenance therapy; this should only be advocated in th

238 daily/maintenance treatment for 5 to 7 days (maintenance therapy: ticagrelor 90 mg BID plus aspirin 8

239 Targeted therapies are being used as maintenance therapy to improve the outcome of ovarian ca

240 py (OAT), such as methadone or buprenorphine maintenance therapy, to optimise HIV outcomes.

241 -week cycles of MPR followed by lenalidomide maintenance therapy until a relapse or disease progressi

242 h nine, and once every 4 weeks thereafter as maintenance therapy until disease progression or unaccep

243 izumab to standard chemotherapy, followed by maintenance therapy until progression, improved the medi

244 e patients were randomly assigned to receive maintenance therapy using BIBF 1120 250 mg or placebo, t

245 It is currently unknown whether a maintenance therapy using FLT3 inhibitors, such as the m

246 Median time receiving maintenance therapy was 9 months after alloHCT and 10.5

247 Ipilimumab 10 mg/kg or placebo maintenance therapy was administered to nonprogressing p

248 single infusion of rituximab (375 mg/m2) as maintenance therapy was administered whenever the freque

249 Maintenance therapy was dasatinib and vincristine/dexame

250 At 3 years, HDIT/HCT without maintenance therapy was effective for inducing sustained

251 In this study, DTG + FTC as maintenance therapy was non-inferior to cART in terms of

252 -elevation myocardial infarction, ticagrelor maintenance therapy was not superior to prasugrel in pre

253 Maintenance therapy was started in 97 patients (34%): 75

254 s given, the total dose received, or whether maintenance therapy was used.

255 Obinutuzumab induction and maintenance therapy was well tolerated with promising ef

256 s cladribine (9 mg/m(2) per day) followed by maintenance therapy, was administered to 27 patients (me

257 ve therapy currently undergoing peri-implant maintenance therapy were recruited.

258 Maintenance therapy, which is designed to prolong a clin

259 es 22 patients receiving regular periodontal maintenance therapy who had one or more periodontal site

260 Patients received 30 courses of maintenance therapy with 6-mercaptopurine, vincristine,

261 ri eradication triple therapy and 8 weeks of maintenance therapy with a proton pump inhibitor; and 4)

262 Groups were given double-blind maintenance therapy with adalimumab at high (40 mg or 20

263 apy was discontinued in patients on combined maintenance therapy with antimetabolites and identified

264 mmunosuppression for all recipients included maintenance therapy with belatacept and mycophenolate mo

265 us, with the clinical responses sustained by maintenance therapy with belimumab, an antibody to B-cel

266 after four cycles were randomly assigned to maintenance therapy with bevacizumab (15 mg/kg), pemetre

267 received prednisone 40 mg/d for 2 weeks and maintenance therapy with budesonide/formoterol 400/12 mu

268 days; thereafter, all the patients received maintenance therapy with itraconazole.

269 22) for up to 12 28-day cycles, followed by maintenance therapy with ixazomib alone.

270 Patients in both groups received maintenance therapy with lenalidomide for 1 year.

271 Maintenance therapy with lenalidomide significantly impr

272 e severely symptomatic disease and value for maintenance therapy with limited potential side effects,

273 tion therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA.

274 or endometrioid EOC should be offered PARPi maintenance therapy with niraparib.

275 lenalidomide (MPR) and compared lenalidomide maintenance therapy with no maintenance therapy in patie

276 Conclusion This study demonstrates that maintenance therapy with norethandrolone significantly i

277 ed trial comparing thalidomide-prednisone as maintenance therapy with observation in 332 patients who

278 Maintenance therapy with olaparib, a poly ADP ribose pol

279 l response were randomly assigned to receive maintenance therapy with one infusion of rituximab every

280 al randomized controlled trial, investigated maintenance therapy with pegylated interferon alfa-2b (I

281 Quality of life during maintenance therapy with pemetrexed is similar to placeb

282 zed phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients wit

283 R-CHOP induction followed by maintenance therapy with rituximab is effective for olde

284 response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, e

285 oved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission.

286 Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improve

287 n each treatment arm, patients received s.c. maintenance therapy with secukinumab 300 mg every 2 week

288 Maintenance therapy with single-agent bortezomib or in c

289 consolidation therapy and up to 12 months of maintenance therapy with single-agent vorinostat.

290 using lymphocyte depletion as induction and maintenance therapy with target of rapamycin inhibitors.

291 We conclude that maintenance therapy with thalidomide-prednisone after au

292 D induction therapy followed by risk-adapted maintenance therapy with the longest follow-up and impor

293 ferent during the index procedure and during maintenance therapy with ticagrelor or prasugrel.

294 on therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10

295 Maintenance therapy with trebananib or placebo continued

296 16 were re-randomized to a 36-week period of maintenance therapy with upadacitinib.

297 Maintenance therapy with ustekinumab, as compared with p

298 "Switch maintenance" therapy with PD-1 blockade at the time of c

299 control, and 67.3% were randomly assigned to maintenance therapy, with 125 and 128 receiving single-a

300 ex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75